Are the Norwegian health research investments in line with the disease burden?
Are the Norwegian health research investments in line with the disease burden?
复制标题
DOI：
10.1186/1478-4505-12-64
复制
发表时间：
2014-11-27
影响因子：
4
通讯作者：
Røttingen JA
中科院分区：
文献类型：
--
作者：
Kinge JM;Roxrud I;Vollset SE;Skirbekk V;Røttingen JA
挪威各治疗领域的研究经费与疾病负担之间的关系尚未得到调查。此外，很少有研究关注国家研究投资与全球疾病负担之间的关联。本研究的目的是利用挪威和全球疾病负担估计来分析挪威在健康研究方面的很大一部分投资与跨治疗领域的疾病负担之间的相关性。我们使用了挪威研究委员会 2012 年的研究投资记录，以及通过地区卫生当局和大学之间的联络委员会分发的投资记录。两者均按健康研究分类系统 (HRCS) 进行分类。此外，我们还使用了 2010 年全球疾病负担项目中挪威和全球的死亡年数和伤残调整生命年 (DALY)。我们创建了一个矩阵，将 HRCS 的支出与全球疾病负担项目的值进行匹配。随着挪威疾病负担以生命损失年数衡量（相关系数 = 0.73），针对特定疾病的研究经费也随之增加。当挪威疾病负担被衡量为伤残调整生命年（相关系数 = 0.62）时，也得到了类似的结果。当使用寿命损失年数（相关系数 = 0.11）和伤残调整生命年（相关系数 = 0.12）时，研究经费与全球疾病负担之间的相关性都很低。一般来说，当挪威的疾病负担与世界其他地区相比相对较高时，研究投资也很高。在整个治疗领域，挪威的研究投资似乎与挪威的疾病负担相一致。挪威的研究投资与全球疾病负担之间的相关性要低得多。本文的在线版本 (doi:10.1186/1478-4505-12-64) 包含补充材料，可供授权用户使用。
The relationship between research funding across therapeutic areas and the burden of disease in Norway has not been investigated. Further, few studies have looked at the association between national research investments and the global disease burden. The aim of the present study was to analyze the correlation between a significant part of Norwegian investment in health research and the burden of disease across therapeutic areas, using both Norwegian and global burden of disease estimates. We used research investment records for 2012 from the Research Council of Norway, and the investment records distributed through liaison committees between regional health authorities and universities. Both were classified by the Health Research Classification System (HRCS). Furthermore, we used the years of life lost and Disability Adjusted Life Years (DALYs) for Norway and globally from the Global Burden of Disease 2010 project. We created a matrix to match the expenditures by HRCS with the values from the Global Burden of Disease project. Disease-specific research funding increased with the Norwegian burden of disease measured as years of life lost (correlation coefficient = 0.73). Similar findings were done when the Norwegian disease burden was measured as DALYs (correlation coefficient = 0.62). The correlation between research funding and the global disease burden was low both when years of life lost (correlation coefficient = 0.11) and DALYs (correlation coefficient = 0.12) were used. Generally, when the disease burden was relatively high in Norway compared with the rest of the world, research investments were also high. Across therapeutic areas, the Norwegian research investments appeared aligned with the Norwegian disease burden. The correlation between the Norwegian research investments and the global disease burden was much lower. The online version of this article (doi:10.1186/1478-4505-12-64) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
4.5
作者：
Carter, Ashley J. R.;Nguyen, Cecine N.
通讯作者：
Nguyen, Cecine N.
影响因子：
158.5
作者：
Gross, CP;Anderson, GF;Rowe, NR
通讯作者：
Rowe, NR
影响因子：
3.7
作者：
Dorsey, E. Ray;Thompson, Joel P.;Moses, Hamilton, III
通讯作者：
Moses, Hamilton, III
影响因子：
11.4
作者：
Mitchell, Rebecca J.;McClure, Rod J.;Watson, Wendy L.
通讯作者：
Watson, Wendy L.
从癌症中丧生（YLL）是人口负担的重要衡量标准，在分配研究基金时应考虑。
影响因子：
8.8
作者：
Burnet, NG;Jefferies, SJ;Benson, RJ;Hunt, DP;Treasure, FP
通讯作者：
Treasure, FP